Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association

. Author manuscript; available in PMC: 2018 Mar 7.

Published in final edited form as: Circulation. 2017 Feb 6;135(10):e604–e633. doi: 10.1161/CIR.0000000000000477

Reviewer Disclosures

Reviewer	Employment	Research Grant	Other Research Support	Speakers’ Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Tyler W. Barrett	Vanderbilt University	NIH NHLBI (PI on a K23 studying A Fib that ended in Sept 2015)^†; Janssen (Site PI for a multicenter international ORBIT-AF II registry)^†; Boehringer Ingelheim (PI for a multicenter retrospective cohort that completed in early 2016)^*	None	None	None	None	Boehringer Ingelheim^†	None
John W. Eikelboom	McMaster University (Canada)	BMS^†; Boehringer Ingelheim^†; Pfizer^†; Bayer^†	None	BMS^†; Boehringer Ingelheim^†; Pfizer^†; Bayer^†; Janssen^; Daiichi Sankyo^	None	None	None	None
David A. Garcia	University of Washington	Daiichi Sankyo (Local PI and St Committee member for clinical trial involving edoxaban)^; Janssen (Local PI for clinical trial)^	None	None	Pfizer^; BMS^	None	Pfizer^; BMS^; Boehringer Ingelheim^*	None
Gregory Y.H. Lip	City Hospital (United Kingdom)	None	None	Bayer^†; BMS/Pfizer^†; Medtronic^†; Boehringer Ingelheim^†; Microlife^†; Roche^†; Daiichi-Sankyo^†	None	None	Bayer/Janssen^†; Astellas^†; Merck^†; Sanofi^†; BMS/Pfizer^†; Biotronik^†; Medtronic^†; Portola^†; Boehringer Ingelheim^†; Microlife^†; Daiichi-Sankyo^†	None
Jeffrey I. Weitz	Thrombosis & Atherosclerosis Research Institute (Canada)	None	None	None	None	None	None	None

This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

Modest.

^†

Significant.